Posts Tagged ‘depression’

DSM: The Book of Woe—Inside the Battle to Define Mental Illness

Monday, December 27th, 2010

Wired—December 27, 2010

by Gary Greenberg

Every so often Al Frances says something that seems to surprise even him. Just now, for instance, in the predawn darkness of his comfortable, rambling home in Carmel, California, he has broken off his exercise routine to declare that “there is no definition of a mental disorder. It’s bullshit. I mean, you just can’t define it.” Then an odd, reflective look crosses his face, as if he’s taking in the strangeness of this scene: Allen Frances, lead editor of the fourth edition of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (universally known as the DSM-IV), the guy who wrote the book on mental illness, confessing that “these concepts are virtually impossible to define precisely with bright lines at the boundaries.” For the first time in two days, the conversation comes to an awkward halt.

But he recovers quickly, and back in the living room he finishes explaining why he came out of a seemingly contented retirement to launch a bitter and protracted battle with the people, some of them friends, who are creating the next edition of the DSM. And to criticize them not just once, and not in professional mumbo jumbo that would keep the fight inside the professional family, but repeatedly and in plain English, in newspapers and magazines and blogs. And to accuse his colleagues not just of bad science but of bad faith, hubris, and blindness, of making diseases out of everyday suffering and, as a result, padding the bottom lines of drug companies. These aren’t new accusations to level at psychiatry, but Frances used to be their target, not their source. He’s hurling grenades into the bunker where he spent his entire career.

One influential advocate for diagnosing bipolar disorder in kids failed to disclose money he received from the makers of the bipolar drug Risperdal.

As a practicing psychotherapist myself, I can attest that this is a startling turn. But when Frances tries to explain it, he resists the kinds of reasons that mental health professionals usually give each other, the ones about character traits or personality quirks formed in childhood. He says he doesn’t want to give ammunition to his enemies, who have already shown their willingness to “shoot the messenger.” It’s not an unfounded concern. In its first official response to Frances, the APA diagnosed him with “pride of authorship” and pointed out that his royalty payments would end once the new edition was published—a fact that “should be considered when evaluating his critique and its timing.”

Frances, who claims he doesn’t care about the royalties (which amount, he says, to just 10 grand a year), also claims not to mind if the APA cites his faults. He just wishes they’d go after the right ones—the serious errors in the DSM-IV. “We made mistakes that had terrible consequences,” he says. Diagnoses of autism, attention-deficit hyperactivity disorder, and bipolar disorder skyrocketed, and Frances thinks his manual inadvertently facilitated these epidemics—and, in the bargain, fostered an increasing tendency to chalk up life’s difficulties to mental illness and then treat them with psychiatric drugs.

The insurgency against the DSM-5 (the APA has decided to shed the Roman numerals) has now spread far beyond just Allen Frances. Psychiatrists at the top of their specialties, clinicians at prominent hospitals, and even some contributors to the new edition have expressed deep reservations about it. Dissidents complain that the revision process is in disarray and that the preliminary results, made public for the first time in February 2010, are filled with potential clinical and public relations nightmares. Although most of the dissenters are squeamish about making their concerns public—especially because of a surprisingly restrictive nondisclosure agreement that all insiders were required to sign—they are becoming increasingly restive, and some are beginning to agree with Frances that public pressure may be the only way to derail a train that he fears will “take psychiatry off a cliff.”

At stake in the fight between Frances and the APA is more than professional turf, more than careers and reputations, more than the $6.5 million in sales that the DSM averages each year. The book is the basis of psychiatrists’ authority to pronounce upon our mental health, to command health care dollars from insurance companies for treatment and from government agencies for research. It is as important to psychiatrists as the Constitution is to the US government or the Bible is to Christians. Outside the profession, too, the DSM rules, serving as the authoritative text for psychologists, social workers, and other mental health workers; it is invoked by lawyers in arguing over the culpability of criminal defendants and by parents seeking school services for their children. If, as Frances warns, the new volume is an “absolute disaster,” it could cause a seismic shift in the way mental health care is practiced in this country. It could cause the APA to lose its franchise on our psychic suffering, the naming rights to our pain.

This is hardly the first time that defining mental illness has led to rancor within the profession. It happened in 1993, when feminists denounced Frances for considering the inclusion of “late luteal phase dysphoric disorder” (formerly known as premenstrual syndrome) as a possible diagnosis for DSM-IV. It happened in 1980, when psychoanalysts objected to the removal of the word neurosis—their bread and butter—from the DSM-III. It happened in 1973, when gay psychiatrists, after years of loud protest, finally forced a reluctant APA to acknowledge that homosexuality was not and never had been an illness. Indeed, it’s been happening since at least 1922, when two prominent psychiatrists warned that a planned change to the nomenclature would be tantamount to declaring that “the whole world is, or has been, insane.”

Some of this disputatiousness is the hazard of any professional specialty. But when psychiatrists say, as they have during each of these fights, that the success or failure of their efforts could sink the whole profession, they aren’t just scoring rhetorical points. The authority of any doctor depends on their ability to name a patient’s suffering. For patients to accept a diagnosis, they must believe that doctors know—in the same way that physicists know about gravity or biologists about mitosis—that their disease exists and that they have it. But this kind of certainty has eluded psychiatry, and every fight over nomenclature threatens to undermine the legitimacy of the profession by revealing its dirty secret: that for all their confident pronouncements, psychiatrists can’t rigorously differentiate illness from everyday suffering. This is why, as one psychiatrist wrote after the APA voted homosexuality out of the DSM, “there is a terrible sense of shame among psychiatrists, always wanting to show that our diagnoses are as good as the scientific ones used in real medicine.”

If bad tests are sanctioned in the DSM, insurance companies might use them to cut off coverage for patients deemed not sick enough. It could be a disaster.

Since 1980, when the DSM-III was published, psychiatrists have tried to solve this problem by using what is called descriptive diagnosis: a checklist approach, whereby illnesses are defined wholly by the symptoms patients present. The main virtue of descriptive psychiatry is that it doesn’t rely on unprovable notions about the nature and causes of mental illness, as the Freudian theories behind all those “neuroses” had done. Two doctors who observe a patient carefully and consult the DSM’s criteria lists usually won’t disagree on the diagnosis—something that was embarrassingly common before 1980. But descriptive psychiatry also has a major problem: Its diagnoses are nothing more than groupings of symptoms. If, during a two-week period, you have five of the nine symptoms of depression listed in the DSM, then you have “major depression,” no matter your circumstances or your own perception of your troubles. “No one should be proud that we have a descriptive system,” Frances tells me. “The fact that we do only reveals our limitations.” Instead of curing the profession’s own malady, descriptive psychiatry has just covered it up.

Read the rest of the article here:

http://www.wired.com/magazine/2010/12/ff_dsmv/all/1

« Return to news items


Share

Will we ever wake up to the deadly risks of happy pills?

Tuesday, December 14th, 2010
The Daily Mail, December 13, 2010
by John Nash

As new research reveals antidepressants raise the danger of heart attacks, the disturbing cost of this modern addiction

Just as David Cameron launches his campaign to boost national happiness, along comes grim news for the 12 million Britons taking happy pills. London-based researchers have just announced that antidepressants raise the risk of fatal heart attacks.

This research is only the latest wake-up call for a nation hooked on happy pills. Might we finally heed the warnings and shake ­ourselves out of our pharmaceutical stupor?

It is high time we did: a small mountain of studies shows that antidepressant drugs are largely ineffective. But more than that, they can ruin lives by creating chronic dependency and a grinding ­hopelessness that ­sometimes leads to self-neglect and death.

The latest study, by Dr Mark Hamer, a ­public health researcher at University ­College ­London, shows that people on the older drugs — tricyclic antidepressants — are at far higher risk of cardiovascular disease than those ­taking the newer class of pills, selective ­serotonin reuptake inhibitors (SSRIs).

But if I were taking SSRIs, I would not be cheered by the findings. Tricyclics were ­discovered in the Forties and it is only now we have identified these dangerous effects.

Moreover, some SSRI drugs are known to cause serious problems such as stomach bleeding. In addition, the withdrawal ­symptoms can be so severe that patients may become dependent on them.

Dr Hamer says his findings do not only affect people with depression, because antidepressants are also prescribed to people with back pain, headache, anxiety and sleeping problems.

Last year, according to Dr ­Hamer’s ­figures, about 33 million antidepressant prescriptions were dispensed in England.

At some point, surely, there will be no one left to prescribe for. In my view, it’s fast becoming one of the greatest medical scandals of our age.

The most worrying thing about these drugs is not their side-effects, but their widespread non-effect: they just don’t work for most ­people with mild to moderate depression.

Two years ago, researchers at Hull ­University concluded that the pills only benefit ­people who are most seriously, clinically depressed. In these extreme cases, there is often a physical problem in their brain, a result of genetics or accident. But what of the rest?

There is a growing view that many people are being needlessly drugged because the natural state of feeling unhappy is viewed as an illness, rather than a ­normal part of life that we should experience and learn from.

An American study of 8,000 ­people who had been treated for depression found that a quarter of them were not clinically sick, but had just undergone a normal life event such as bereavement.

Their symptoms, it said, should be left to pass naturally (that, of course, would be a blow to the drug manufacturers, who profit so handsomely from the mass ­consumption of their mind-numbing chemicals).  For most of us, the healthiest option is to face our problems, rather than disappear down a black hole of antidepressant dependency.

One leading expert, Randolph Nesse, a psychiatry professor at Michigan University, argues that this mild form of depression is ­beneficial, often ­interjecting in life to tell us to stop what we are doing and reconsider.

This can help, he says, when something awful happens to us, such as a job loss or relationship break-up, when it makes sense to slow down to grieve, reassess and make changes.

But instead, we live in a world that tells us that when we feel out of sorts we need a pill to recover.

It is this belief that ­creates queues of patients at the doors of hard-pressed GPs, who often feel they have no option but to hand out happy pills as though they were sweeties.

Many patients later claim they couldn’t have coped without them. They will swear that ‘the drugs make me feel better, so they must be working’. But often the drugs do not actually work as chemicals. Instead, they merely reassure us — the so-called placebo effect.

In 2008, Professor Irving Kirsch at Hull University found something strange when he took a close look at some figures from drug manufacturers’ own trials of four common antidepressants.

The drugs improved patients’ sense of wellbeing. So far, so ­unremarkable.

But many of those involved in the trials were given sugar pills instead of antidepressants.

And their depression scores improved just as much as those on the real pharmaceuticals. In other words, the placebo patients put so much store by the magical (and much-promoted) power of antidepressants that they lifted their own morale without any genuine chemical intervention. Such is the life-enhancing power of human belief.

Everybody hurts: Sadness is a part of life and shouldn’t always be treated as an illness

But this phenomenon also has a dark side: the opposite of placebo, which is called the ‘nocebo’ effect.

This occurs when you convince someone that a particular thing will do them harm, and they begin to feel sick.

Talk to someone about food poisoning while they are tucking into a hearty meal and you will see the nocebo effect at work.

Sadness is a part of life and shouldn't always be treated as an illness

Something similar is happening in our pill-obsessed world. When we are convinced that we need drugs to get us out of an ­emotional crisis, we stop doing things to help ourselves.

This was clear from the latest research. Dr Hamer found that tricyclic drugs raise a person’s heart attack risk.

But that risk was dwarfed by another danger: the people ­taking the drugs often lost the will to look after themselves properly. They were more likely to smoke, be overweight and not exercise.

Dr Hamer says that if they started living more healthily they would cut their heart attack risk by three times. Exercise and weight loss would also help alleviate their depression and anxiety.

But people stuck in the role of helpless drug-munchers often ­cannot make that change for themselves.

They simply sit waiting for their questionable pills to work. And when the pills fail, they become even more demoralised. It’s a vicious cycle, and one that’s ­sucking in more and more vulnerable people.

Read more: http://www.dailymail.co.uk/health/article-1338340/Will-wake-deadly-risks-happy-pills.html#ixzz186xwdATE

« Return to news items


Share

Doctor: Paxil “Especially Notorious” for Causing Withdrawal

Monday, October 11th, 2010

Note from CCHR: To see the 42 international warnings/studies on Paxil visit our psychiatric drug side effects search engine http://www.cchrint.org/psychdrugdangers/drug_warnings.php or watch this video on Paxil causing addiction/withdrawal featuring attorney Karen Barth Menzies http://www.youtube.com/watch?v=Mpex0n0DXuc

Lawyers and Settlements

October 9, 2010

Atlanta, GA: There are a number of Paxil side effects associated with the antidepressant, and some patients continue to experience these effects even after discontinuing use of the drug.

Doctor: Paxil "Especially Notorious" for Causing WithdrawalDr. Charles Raison, an associate professor at Emory University, wrote in response to a reader’s question on CNN that about 20 percent of patients experience withdrawal symptoms when they stop taking antidepressants.

Raison says that the common symptoms of antidepressant withdrawal include dizziness, anxiety, sensory disturbances and flu-like symptoms.

According to Raison, coming off the medication slowly is important.

“The trick to lowering your chances of having these symptoms is to reduce the dose of the antidepressant as slowly as possible,” he writes. “For people who are really sensitive it can take months to get off an antidepressant slowly enough to avoid withdrawal symptoms.”

Raison also said that Paxil is “especially notorious for causing withdrawal problems” because of its short half-life in the body.

Paxil is also associated with a number of side effects for those currently taking the medication, including birth defects and depression.

Read the rest of the article here http://www.lawyersandsettlements.com/articles/15134/paxil-birth-defects-side-effects-pph-7.html

« Return to news items


Share

Note to all press running “ADHD linked to depression/suicide” study—its bogus

Tuesday, October 5th, 2010

by CCHR International

A cursory look at the study purporting that “ADHD in Children Linked to Depression and Higher Suicide Risk” revealed its obvious and glaring flaws, and we are forced to ask why so-called medical websites such as WebMD or Medical News Today were unable to accomplish what took us about œ hour to uncover—what was clearly omitted from this “study.”

The study claims that “Children who are diagnosed with ADHD (Attention-Deficit/Hyperactivity Disorder) have a higher chance of developing  depression and/or attempting suicide during their teenage years, or 5 to 13 years after being diagnosed, say researchers in a new article published in Archives of General Psychiatry..”

Why none of the press or medical websites are questioning what drugs the “ADHD” children in this study were already taking and what effect this could have on developing depression or suicidality…. we leave to the reader.   But this is fact; the stimulant drugs such as  Ritalin, Concerta, Adderall, etc, that are prescribed to children diagnosed with  “ADHD” have been documented by the FDA to have side effects including hallucinations, delusional thinking, mania, psychosis, aggression, violence, hostility, drug dependence and suicide and depression. The documented side effects and international drug regulatory warnings on these drugs (including withdrawal) can be found here: http://www.cchrint.org/psychdrugdangers/drug_warnings.php

The study itself reveals that the “ADHD” children being studied were from Pittsburgh and Chicago—and this key fact; all the “ADHD” children from Chicago  were recruited from a child psychiatric clinic and  42% of the “ADHD” children from Pittsburgh were also recruited from a psychiatric clinic.

The fact that the children diagnosed ADHD were recruited from psychiatric clinics nearly guarantees they were already taking psychiatric drugs or minimally had been on these drugs at some point to “treat” their ADHD diagnoses.   Moreover,  those “ADHD” children in the study who the researchers claim “developed depression,” not only should we know whether they were already on stimulant drugs which caused these side effects, but also if they were subsequently prescribed antidepressants to “treat” the depression,  considering antidepressants carry black box warnings for suicidality and also are known to cause worsening depression.

The main issue here is why none of those publishing and thereby promoting the content of this study as factual bothered to pose these simple, logical questions, or read the study themselves before passing it on as factual, potentially influencing the public at large with something that could effect their lives or the lives of their children.

As a side note…Two of the listed study authors are:

Dr. Andrea Chronis-Tuscano,  has received research support and honoraria from McNeil Pediatrics.  McNeil Pediatrics  is a division of Ortho-McNeil Janssen pharmaceuticals Inc which sells Concerta.

Dr. William E.  Pelham has received research support from Eli Lilly and honoraria from Janssen Pharmaceuticals.

And that, is the story that isn’t being told.

« Return to news items


Share

PTSD and Anti-Depressant Drugs: the Worst Notorious Modern Medical Fraud

Tuesday, September 21st, 2010

Salem-news.com

September 21, 2010

by Dr. Phillip Leveque

Afghanistan
Afghanistan by Tim King Salem-News.com

(MOLALLA, Ore.) – I’m sure some people will take umbrage at my title. Keep on reading. First of all there are about 30 of them – why? It’s easy, most don’t work. In fact placebos (fake sugar pills) frequently work better.

Another point, their adverse side effects are horrible. Some even cause worse depression and even suicide. The main side effects are nausea, insomnia, anxiety, restlessness, decreased sex drive, dizziness, weight gain or loss, tremors, sweating, sleepiness, fatigue, dry mouth, diarrhea, constipation, headache, et cetera. Who needs that stuff?!? They also screw up ones head and balance with falls and fractures. If one stops taking them, the withdrawal symptoms sound worse than heroin. In addition to all this, some are addicting and it is very difficult to stop taking them.

This kind of drug or drugs has an extremely interesting origin. Around 1950 the first drug in this class was actually an anti-tuberculosis drug Isoniazid. For some reason it also acted as a brain stimulant, much like amphetamine. When this side effect was published by the T.B. doctors, other doctors decided to try it on depression patients. Prior to this certain Morphine-like cousin drugs and amphetamines were used for depression. They had severe addiction liability.

Isoniazid, the T.B. drug, was used on an experimental basis and the patients brain function improved dramatically. The psychiatrists who read about this tried Isoniazid on their depression patients and they coined the word ANTI-DEPRESSANT.

From then on starting about 1957 the Tricyclic drugs were born. They were relatives of anti-histamine drugs and they did combat depression. I think the first well known one was Elavil which is still in use. This type of drug drifted around quietly for several years searching for a disease all of the sudden it erupted – CLINICAL DEPRESSION. The first REAL drug Fluoxetine or PROZAC came out in 1988 by Ely Lilly & Co. It was heavily advertised and we soon had a epidemic of clinical depression spread all over the world.

I’m not going into a recital of the various kinds of anti-depressants. I think there is enough to indicate that at least 500,000,000 prescriptions are written per year and for the 14 or so leaders, each is worth up to several billion dollars to the drug companies.

As I said in the beginning placebos, or fake pills, work about as well as these chemicals and exercise or just plain talking to a psychologist may work as well. The drug companies advertise heavily in the millions of dollars to sell these drugs to doctors and patients. It is worth it. The anti-depressants bring in billions of dollars.

A side comment is that the drug companies have sold the idea to the Veterans Administration and they prescribe these drugs by the ton to PTSD Veterans. The evidence is that they don’t help much and cause a lot of harm.

http://www.salem-news.com/articles/september212010/ptsd-depressants-pl.php

« Return to news items


Share

Stop the Stigma of Mental Illness? Try Stopping the Pharma Funded Campaigns & Groups Behind the “Stigmatizing”

Friday, September 17th, 2010

(Image taken from: http://herinst.org/sbeder/corppower/pharm-agenda.html)

by CCHR Int

A new study, the result of a joint collaboration between Indiana University and Columbia University, and published  by the American Journal of Psychiatry, reports that prejudice and discrimination still exists among people with serious mental illness.  Headlines include “Mental Illness Stigma Hard to Shake, Survey Finds” and “Despite Deeper Understanding of Mental Illness, Stigma Lingers.”

So what exactly is behind this study? Taking aside the fact that Columbia University is well known for its collaboration with pharmaceutical companies, its medical center having collaborated with AstraZeneca, GlaxoSmithKline, Janssen Pharmaceutica, Merck, Novartis and Pfizer. Or the fact that Indiana University received a $1 million grant from Eli Lilly.

With a seemingly altruistic agenda, the fact is the campaign to end the “stigma” of mental illness is one driven and funded by those who benefit from more and more people being labeled mentally ill—pharma, psychiatry and pharmaceutical front groups such as  NAMI and CHADD to name but a few.   For example, take NAMI’s campaign to stop the “stigma” and “end discrimination” against the mentally ill—the “Founding Sponsors” were Abbott Labs, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer, Novartis, SmithKline Beecham and Wyeth-Ayerst Labs. (For an in-depth look at what else Pharma funds and how this funding not only helps set mental health policies but campaigns such as this, read Pharmaceutical Industry Agenda Setting in Mental Health Policies at the bottom of this post)

The fact is that the  “stigmatization ” is coming from those that benefit from people being labeled/stigmatized with mental disorders that have no medical/biological evidence. Case in point, if you are rebellious, you are “stigmatized” with the label “oppositional defiant disorder.” If your kid acts like a kid he is “stigmatized” with the label “ADHD.” If you are sad, unhappy (even temporarily) you are “stigmatized” with the label “depressive” or “bi-polar disorder.” If you are shy you are “stigmatized” with the label “social anxiety disorder.” Moreover, you or your child are now stigmatized for life as this label, which is based solely on opinion, is now part of your medical record, despite the fact there is no medical evidence to prove you are “mentally ill”.

This is also true of people diagnosed “schizophrenic.” There is no medical test to verify someone has a brain abnormality or medical condition of schizophrenia. And while no one claims  people can’t become psychotic, the fact remains there is no biological evidence to support schizophrenia as a brain disease or chemical abnormality.  And consider this, if people do become psychotic, or irrational,  is it in fact caused by some  underlying medical (not psychiatric) problem?   And why did a 15-year multiple follow up study find that there was a 40% recovery rate for those diagnosed schizophrenic who did not take antipsychotics, versus a 5% rate for those who did?  What happened to their supposed “brain disease?” Did it simply vanish?  Moreover, if they could recover from such a mental state, do they deserve the “stigma” of “schizophrenia” still being part of their permanent medical record?  For life?   Think about it.  Imagine you were extremely overweight—obese.  You lose all the weight so you are no longer obese.  Yet your medical records continue to say that you are.

And if schizophrenia is in fact a “disease” despite the fact there is no medical or biological evidence (note we did not say speculation, or theories, but evidence) then why is it that psychiatrist Loren Mosher, the former Chief of Schizophrenia Research for the National Institute of Mental Health (NIMH) openly state that there is no biological condition of schizophrenia as a disease or brain malfunction? And why didn’t the mental health industry take advantage of his 2-year-outcome studies proving that those diagnosed schizophrenic could recover without the use of drugs? Is it because this proved that recovery was possible and thereby disproved the theory that something was wrong with their brain? Or was it the fact that they recovered without the use of drugs, thereby threatening a multi-billion dollar pharmaceutical industry?  Maybe this explains why Mosher was fired from his position at NIMH (http://www.moshersoteria.com/)

As a final note regarding “stigmatization,” keep in mind that psychiatrists admit there is no recovery from “mental illness.” They admit no cures. So once you are labeled—game over.

The new “study” also reports, ” more people now believe that illnesses like schizophrenia and depression are caused by chemical imbalances in the brain.”  This is marketing at its best—say people believe in a chemical imbalance so you don’t have to bother pointing out the fact that there is no chemical imbalance .  How can the layperson be sure of this? It’s simple. Find one person who has a lab test showing their chemical imbalance.  Not one of the millions of people taking drugs to cure their “chemical imbalance” has a lab test showing they have an imbalance.  Now it really doesn’t take a rocket scientist to figure that out… does it?

For more information  about pharmaceutical front groups see this:  http://www.cchrint.org/psycho-pharmaceutical-front-groups/

For an in-depth look at this topic, read Pharmaceutical Industry Agenda Setting in Mental Health Policies


Abstract: The development of political agenda-setting through the use of sophisticated public relations techniques is threatening to undermine the delicate balance of representative democracy. This has important ramifications for policies aimed at providing mental health services and the implementation of mental health laws. The principal agenda setters in this area are pharmaceutical companies with commercial reasons to promote public policies that expand the sales of their products. They have manufactured highly effective advocacy coalitions that incorporate front groups in order to set the policy agenda for mental health. However, policies tailored to their commercial purpose are not necessarily beneficial either for patients or the society at large.



« Return to news items


Share

Psychotropic Drugs, Our Children and Our Pill-Crazed Society

Wednesday, September 8th, 2010

The Huffington Post
By Dr. Ronald Ricker and Dr. Venus Nicolino
September 8, 2010

Today, the use of psychoactive drugs by children (6-17) is all too common, relied on far too much and growing at an alarming rate. It all started in the ’70s.

Memorialized in 1966 by the Rolling Stones’ “Mothers Little Helpers,” it was at that time that our society took the first steps at becoming “Pill Crazy.” Valium and Librium and Quaaludes were “Mother’s Little Helpers. The first drugs to enter the stage. If you couldn’t stand Johnny, your friends, your husband, in-laws, etc, tranquilizers smoothed you out, made you tranquil. Not surprisingly, in the 70s, the consumption of these tranquilizers, once discovered and available, skyrocketed. Anxiety was the popular diagnosis. Antidepressants were beginning to raise their heads as well. Their popularity at that time, however, was muted by the fact that they didn’t work well, and also sported many side effects, some of which were very annoying and occasionally dangerous. And, no one knew what was just around the corner.

Prozac

Prozac was first marketed in 1987. It was a totally new type of antidepressant, which seemed to work and had far less side effects. What had been a stream of tranquilizers became a tsunami of Prozac’s and tranquilizers. Other ‘Prozac’s’ entered the scene–Zoloft, Celexa, Paxil and Luvox, all vying to take part of Prozac’s market share. Promotion of these drugs by drug manufacturers exploded. Where there had been a surge in the diagnosis of anxiety, now the diagnosis of the decade was ‘depression.’ Housewives by the droves needed and demanded antidepressants and even more tranquilizers. If one was good, two must be better. The pill craze was on.

Diagnoses started to morph. The more the diagnoses, the more opportunities to sell drugs. Anxiety became anxiety neurosis, panic disorder, panic attacks, etc. ‘Depression,’ as a diagnosis, was of course and remains very popular. However, many patients don’t and didn’t like that diagnosis–perhaps it sounded too much like a disease. So a new depression explanation and diagnosis emerged–’chemical imbalance,’ which sounded more sheik and less like a disease and, of course, yielded more customers.

Not far behind ‘chemical imbalance’ came ‘mood disorder,’ a special type of depression, also called bipolar disorder. There are people who actually have a bipolar disorder and require numerous special medications for treatment. These medications, mood stabilizers, antidepressants, and second generation antipsychotics are far more dangerous medications than Prozac and tranquilizers. Further, there are also many people who are said to have ‘bipolar disorder’ who don’t. Often these patients are those who were said to be depressed yet don’t get better with standard antidepressants. They get all the special and dangerous medications (the number of which is multiplying geometrically) and have the additional advantage of being able to excuse pretty much anything they do as a result of their ‘mood disorder.’

This pretty well takes us through the ’90s. But here come our children. How did our children get sucked into all this? Our pill craze was and is a huge part. Parents and physicians often subscribe to this theory, that there is a pill for everything. Mommy says Johnnie is depressed, doctor agrees, Johnnie doesn’t. Guess who wins? Certainly not Johnny. Guess what Johnnie gets? A pill, usually an SSRI, which he may end up taking for a long time. Assuming Johnnie takes three years of SSRI therapy, his diagnosis is changed 25 percent of the time, usually to the much more serious diagnosis, bipolar disorder. His medications are changed to a much more serious and dangerous types. If Johnny takes an SSRI for six years the chances of his diagnosis changing to bipolar increases to 50 percent. So do his meds.

There’s yet another and newer mine field for Johnnie to negotiate, new in the last two decades. Let’s say Johnnie fidgets in his seat, doesn’t listen to the teacher, hates to read, and talks to his neighbor all the time. Guess what. Johnnie is diagnosed with ADHD (attention deficit hyperactivity disorder) and given another serious type of drug, a stimulant–usually Ritalin or a form of speed (one example being Adderall). Did you know that Adderall is 100 percent speed? We know speed kills but give it to our children. Think about that. Speed kills and we give speed to our children, masked as Adderall.  Astounding.

Read entire article here:  http://www.huffingtonpost.com/dr-ronald-ricker-and-dr-venus-nicolino/psychotropic-drugs-our-ch_b_680488.html

« Return to news items


Share

The Over-Prescribing of Psychoactive Drugs to Children: A Scourge of Our Times

Wednesday, September 1st, 2010

The Huffington Post

September 1, 2010

by Dr. Ronald Ricker and Dr. Venus Nicolino

Today, the administration of psychoactive drugs to children (6-17) is all too common and growing at an alarming rate. These drugs often cause the opposite of the intended effect, often condemning children to a life of misery and ill health. The prescription of these drugs is said to treat “chemical imbalances” which were said to cause ADHD, Depression and Bi-polar disorder. It turns out, however, that what we were calling “disease-causing chemical imbalances,” is simply incorrect . The sad irony is, the inappropriate use of these medications is in fact creating different chemical imbalances, which do cause mental disorders, many of which are both life-long and debilitating.

Furthermore, it is now clear that often we are diagnosing ordinary childhood and adolescent behavior as mental disorders (Wait, children are supposed to be bursting with energy? It’s normal for a teenager to be moody and aloof?). This diagnosing is not only based on this idea of “chemical imbalances,” but also a general and pervasive notion that every non-acceptable behavior is due to a mental illness. And last, but certainly not least, the prescribing of these medications by doctors is based on the disinformation provided them by the FDA, drug manufactures and often fraudulent studies, all in the name of making money, on the backs of our children.

In a recent lecture, respected journalist, writer and Nobel Prize Nominee, Robert Whitaker (PBS, Boston, June 15, 2010) highlighted not only the appallingly unscientific methodology used in the development, prescription and use of psychotropic drugs in school-aged children, but also how hopelessly corrupt and failed the systems that should be regulating the safety of medicines are in this country.

Unfortunately, many drug companies exist for one reason: to make money. As such, the people who run these companies have developed a worldview bereft of any more notion of ethics or morality than British Petroleum. Some drug companies’ success is not based on a drug’s usefulness or the safety of its products, but whether it makes money. The path to more money is simple: find new uses for their old drugs, invent new drugs and find new markets for both new and old drugs. Unfortunately, children are today’s newest market.

The FDA requires a “Successful Drug Trial” to approve new medications. “Trial” is often a misnomer, as the word implies some notion of impartiality and unknown outcome. These “trials” often are more like kangaroo courts. In one “trial,” in this case to prove the usefulness of Prozac, corruption and dishonesty were the rule. Children who responded to placebos were removed from the data, as were negative responders to the actual drug. This meant that the only children who were left in the study group were so-called “positive responders.” And, even then, the researchers and doctors, whose “research” funding was provided by the makers of Prozac, were the very ones to decide which subjects, if any, actually did respond “positively” to the drug. This, of course, is a massive conflict of interest. The doctors, researchers and drug companies all want the same thing — FDA approval and to make more money.

In a 2004 article published in perhaps the most prestigious British medical journal, Lancet, said the trial studies used to provide proof of the usefulness of anti-depressant drugs in children, were “nothing but fraudulent.” Following that assessment, all anti-depressants but Prozac were banned in the UK for use on children. (The fact that Prozac was not banned was based on very dubious, some say dishonest, research as documented above).

The true damage caused by the use of anti-depressant drugs like Paxil, Zoloft, Prozac, etc. (AKA of SSRI’s: Selective serotonin reuptake inhibitors) by school-aged children is only found by legitimate, longer studies, like those that continued from 17 months to six years. In one study, 25 percent of children who had been on SSRI’s for three years were re-diagnosed with the much more serious disorder of Bi-polar disease. This number increased to 50 percent after six years of SSRI use. Long-term use of new anti-psychotics may lead to even greater problems than the initial disease. Diabetes, morbid obesity and early death have all been linked to the use of these drugs. And, as written by us in a previous blog both short and long term use of stimulant drugs such as Adderall), have numerous serious side effects.

Read the rest of this article here: http://www.huffingtonpost.com/dr-ronald-ricker-and-dr-venus-nicolino/the-prescribing-of-psycho_b_665838.html

Note: To view all international drug regulatory warnings and studies on psychiatric drugs including those issued specifically for children,visit CCHR’s psychiatric drug search engine here: http://www.cchrint.org/psychdrugdangers/drug_warnings.php

Also see this video – Drugging Our Children: Side Effects – http://www.cchrint.org/videos/

« Return to news items


Share

New Review of FDA antidepressant drug trials suggests antidepressants only “marginally better” than placebo – Ineffectiveness of antidepressants called “jaw-dropping”

Tuesday, August 24th, 2010

Medscape
By Deborah Brauser
August 24, 2010

A new review of 4 meta-analyses of efficacy trials submitted to the US Food and Drug Administration (FDA) suggests that antidepressants are only “marginally efficacious” compared with placebo and “document profound publication bias that inflates their apparent efficacy.”

In addition, when the researchers also analyzed the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, “the largest antidepressant effectiveness trial ever conducted,” they found that “the effectiveness of antidepressant therapies was probably even lower than the modest one reported…with an apparent progressively increasing dropout rate across each study phase.

“We found that out of the 4041 patients initially started on the SSRI [selective serotonin reuptake inhibitor] citalopram in the STAR*D study, and after 4 trials, only 108 patients had a remission and did not either have a relapse and/or dropped out by the end of 12 months of continuing care,” lead study author Ed Pigott, PhD, a psychologist with NeuroAdvantage LLC in Clarksville, Maryland, told Medscape Medical News.

Sustained Benefit “Jaw Dropping”

“In other words, if you’re trying to look at sustained benefit, you’re only looking at 2.7%, which is a pretty jaw-dropping number,” added Dr. Pigott.

Overall, “the reviewed findings argue for a reappraisal of the current recommended standard of care of depression,” write the study authors.

“I believe there are likely some people where [antidepressants] are truly beneficial beyond placebo. The problem right now is that we simply have no way of knowing who those people are,” noted Dr. Pigott. “My hope is that this kind of analysis creates ‘more oxygen’ for looking at other kinds of approaches to treatment.”

The study was published in the August issue of Psychotherapy and Psychosomatics.

When registering new drug application trials with the FDA, drug companies must prespecify the primary and secondary outcome measures, the investigators report. “Prespecification is essential to ensure the integrity of a trial and enables the discovery of when investigators selectively publish the measures that show the outcome the sponsors prefer following data collection and analysis, a form of researcher bias known as HARKing or ‘hypothesizing after the results are known’,” they write.

For this article, Dr. Pigott and his team reviewed the following meta-analyses:

  • 1. Rising and colleagues (reviewed all efficacy trials for new drugs between 2001 and 2002)
  • 2. Turner and colleagues (reviewed 74 past trials of 12 antidepressants)
  • 3. Kirsch and colleagues, 2002 (reviewed 47 trials of 6 FDA-approved antidepressants)
  • 4. Kirsch and colleagues, 2008 (reviewed depression severity and efficacy in 35 trials)

The researchers also sought to reevaluate the methods and findings of STAR*D, a randomized, controlled trial of patients with depression. Its prespecified primary outcome measure was the Hamilton Rating Scale for Depression (HRSD), whereas the Inventory of Depressive Symptomatology–Clinician-Rated (IDS-C30) was secondary for identifying remitted and responder patients.

“STAR*D was designed to identify the best next-step treatment for the many patients who fail to get adequate relief from their initial SSRI trial,” the study authors write.

“When I first read about STAR*D’s step 1 phase, it just seemed biased to me,” explained Dr. Pigott. “I thought of it as the ‘tag, you’re healed’ research design. Patients who were scored as having a remission during the first 4 to 6 weeks of up to 14 weeks of acute care treatment were counted as remitted, taken out of the subject pool, and put into the follow-up care phase. In other words, they didn’t have the ability to have a relapse. But as most people know, depression ebbs and flows.

“So what made me want to continue to follow this study was that it became clear that the only way that people were really going to be able to evaluate the antidepressants’ effectiveness was to wait for the publication of the follow-up findings,” he added. “After their major final summary study was published, I felt as though the results weren’t really being portrayed in a manner that was consistent with the study’s prespecified criteria.”

High Dropout, Low Remission Rates

In addition to reporting on low efficacy of antidepressants compared with placebo, the 4 meta-analyses “also document a second form of bias in which researchers fail to report the negative results for the prespecified primary outcome measure submitted to the FDA, while highlighting in published studies positive results from a secondary or even a new measure, as though it was their primary measure of interest,” the investigators write.

For example, they note, the meta-analysis from Rising and colleagues found that studies with favorable outcomes were almost 5 times more likely to be published and that over 26% of primary outcome measures were left out of journal articles. Turner and colleagues found that antidepressant studies were 16 times more likely to be published if favorable compared with those with unfavorable outcomes.

In reanalyzing the STAR*D methods, the researchers found that the high dropout rate resulted in frequently missed exit HRSD and IDS-C30 interviews. So the revised statistical analytical plan dropped the IDS-30 for the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), which was given at each visit.

“Even with the extraordinary care of STAR*D, only about one fourth of patients achieved remission in step 1 [and] the dropout rate was slightly larger than the success rate,” the study authors write. Steps 2 through 4 also each showed increasingly fewer success rates and larger dropout rates.

Of the 4041 patients at the study’s initiation, 370 (9.2%) dropped out within 2 weeks, and only 1854 patients (45.9%) obtained remission “using the lenient QIDS-SR criteria.” Of these, 670 dropped out within a month of their remission, and only 108 “survived continuing care” and underwent the final assessment.

Dr. Pigott described reanalyzing STAR*D as being “a bit like an onion. Each time we thought we understood the results, we found another layer. It wasn’t until about a year and a half ago that we discovered that the secondary outcome measure, the QIDS-SR, was not originally supposed to be used as a research measure. What was particularly disconcerting to me was that in their summary article, they basically used the QIDS-SR to report all of the results, which clearly had an inflationary effect on the outcome.”

He also noted that STAR*D did not have a placebo design. “Because the patients knew they were receiving the active medication, I would have expected a higher remission rate than what you’d find normally in a placebo-controlled study.

“The inescapable conclusion from the STAR*D results is that we need to explore more seriously other forms of treatment (and combination thereof) that may be more effective. This effort will require developing new service delivery models to ensure that as treatments are identified, they are widely implemented,” the investigators conclude.

Read entire article here:  http://www.medscape.com/viewarticle/727323
(Free registration required)

« Return to news items


Share

People & Power—Drug Money

Tuesday, August 17th, 2010

A 23 minute TV expose on Big Pharma by ALJAZEERA (see video at bottom of this page)

This piece pulls no punches exposing the rampant fraud, fatal drug side effects, off label marketing, criminal practices  and “absolutely jaw dropping” payouts Pharma makes to psychiatrists/doctors.

  • “There is so much money to be made in stealing from the United States Healthcare system,” says Patrick Byrnes, Taxpayers Against Fraud.
  • Lewis Morris, US Department of Health states, “One of the things we are now looking at is going after the executives in these companies and holding them personally accountable.”
  • Sharon Ormsky, FBI Financial Crimes Unit states, “Pharmaceutical fraud is one of our top three threats — everybody is touched by these frauds in the extent that when you look at the billions of dollars that go into healthcare for the United States, a good percent,  3-10% of that is believed to be siphoned off into fraud—that’s  money that  could be going to very needy patients.”

Now the U.S. government is fighting back.  In the last two years alone, the  government has fined six of America’s  top ten pharmaceutical companies for fraud.  Investigations are ongoing against another three.  In this period the industry has had to pay out over 5 billion dollars in fines, and topping the list is drug giant Pfizer, having recently settled civil & criminal charges resulting in $2.3 billion dollars —the biggest fraud case, the biggest criminal case, the biggest false claims act in U.S. history.   ALJAZEERA also exposes Pfizer’s “interesting way of doing business.  Witnesses in the case revealed just how the company persuaded doctors to prescribe its drugs. It entertained them in strip clubs, it told them that the blues teenagers feel when they don’t make the football team was signs of treatable depression and it paid them to endorse Pfizer drugs. One doctor received $150,000 in a year.

Also highlighted is the current scandal regarding antipsychotic drugs, including state law suits, dangerous documented side effects and how federal investigators are now looking into claims drug company Johnson & Johnson illegally marketed their antipsychotic drug Risperdal to children, paying “some of the most influential doctors in the field” in order to accomplish this.  And leading that pack sits none other than the  [now] infamous psychiatrist Joseph Biederman, who has been “credited” with the huge increase of children prescribed psychiatry’s most powerful/dangerous drugs, antipsychotics, while receiving millions in Pharma kickbacks that he failed to disclose.   Biederman is shown on tape being questioned under oath, and when asked “What rank are you?” Biederman responds, “Full Professor.” When asked “What comes after that?” Biederman responds, “GOD.”

This is a 23 minute expose well worth watching.

This is one of the best exposĂ©’s on Big Pharma we’ve seen:

People & Power —Drug Money, produced by ALJAZEERA.  This piece pulls no punches exposing the rampant fraud, fatal drug side effects, off label marketing, criminal practices  and “absolutely jaw dropping” payouts Pharma makes to psychiatrists/doctors.

* “There is so much money to be made in stealing from the United States Healthcare system,” says Patrick Byrnes, Taxpayers Against Fraud.

* Louis Morris, US Department of Health states, “One of the things we are now looking at is going after the executives in these companies and holding them personally accountable.”

*Sharon Ormsky, FBI Financial Crimes Unit states,  ”Pharmaceutical fraud is one of our top three threats — everybody is touched by these frauds in the extent that when you look at the billions of dollars that go into healthcare for the United States, a good percent,  3-10% is believed to be siphoned off into fraud that’s  money that  could be going to very needy patients.”

Now the U.S. government is fighting back.  In the last two years alone, the  government has fined six of America’s 10 pharmaceutical companies for fraud.  Investigations are ongoing into another three.  In this period the industry has had to pay out over 5 billion dollars in fines, and topping the list is drug giant Pfizer, having recently settled civil & criminal charges resulting in $2.3 billion dollars —the biggest fraud case, the biggest criminal case, the biggest false claims act in U.S. history.   ALJAZEERA also exposes Pfizer’s “interesting way of doing business.  Witnesses in the case revealed just how the company persuaded doctors to prescribe its drugs. It entertained them in strip clubs, it told them that the blues teenagers feel when they don’t make the football team was signs of treatable depression and it paid them to endorse Pfizer drugs. One doctor received $150,000 in a year.

Also highlighted is the current scandal regarding antipsychotic drugs, including state law suits, dangerous documented side effects and how federal investigators are now looking into claims drug company Johnson & Johnson illegally marketed their antipsychotic drug Risperdal to children, paying “some of the most influential doctors in the field” in order to accomplish this.  And leading that pack sits none other than the  [now] infamous psychiatrist Joseph Biederman, who has been “credited” with the huge increase of children prescribed psychiatry’s most powerful/dangerous drugs, antipsychotics, while receiving millions in Pharma kickbacks that he failed to disclose.   Biederman is shown on tape being questioned under oath, and when asked “What rank are you?” Biederman responds, “Full Professor.” When asked “What comes after that?” Biederman responds, “GOD.”

This is a 23 minute expose well worth watching.

http://www.youtube.com/watch?v=1TwdsYVHjGA&feature=player_embedded#!

This is one of the best exposĂ©’s on Big Pharma we’ve seen:

People & Power —Drug Money, produced by ALJAZEERA.  This piece pulls no punches exposing the rampant fraud, fatal drug side effects, off label marketing, criminal practices  and “absolutely jaw dropping” payouts Pharma makes to psychiatrists/doctors.

* “There is so much money to be made in stealing from the United States Healthcare system,” says Patrick Byrnes, Taxpayers Against Fraud.

* Louis Morris, US Department of Health states, “One of the things we are now looking at is going after the executives in these companies and holding them personally accountable.”

*Sharon Ormsky, FBI Financial Crimes Unit states,  ”Pharmaceutical fraud is one of our top three threats — everybody is touched by these frauds in the extent that when you look at the billions of dollars that go into healthcare for the United States, a good percent,  3-10% is believed to be siphoned off into fraud that’s  money that  could be going to very needy patients.”

Now the U.S. government is fighting back.  In the last two years alone, the  government has fined six of America’s 10 pharmaceutical companies for fraud.  Investigations are ongoing into another three.  In this period the industry has had to pay out over 5 billion dollars in fines, and topping the list is drug giant Pfizer, having recently settled civil & criminal charges resulting in $2.3 billion dollars —the biggest fraud case, the biggest criminal case, the biggest false claims act in U.S. history.   ALJAZEERA also exposes Pfizer’s “interesting way of doing business.  Witnesses in the case revealed just how the company persuaded doctors to prescribe its drugs. It entertained them in strip clubs, it told them that the blues teenagers feel when they don’t make the football team was signs of treatable depression and it paid them to endorse Pfizer drugs. One doctor received $150,000 in a year.

Also highlighted is the current scandal regarding antipsychotic drugs, including state law suits, dangerous documented side effects and how federal investigators are now looking into claims drug company Johnson & Johnson illegally marketed their antipsychotic drug Risperdal to children, paying “some of the most influential doctors in the field” in order to accomplish this.  And leading that pack sits none other than the  [now] infamous psychiatrist Joseph Biederman, who has been “credited” with the huge increase of children prescribed psychiatry’s most powerful/dangerous drugs, antipsychotics, while receiving millions in Pharma kickbacks that he failed to disclose.   Biederman is shown on tape being questioned under oath, and when asked “What rank are you?” Biederman responds, “Full Professor.” When asked “What comes after that?” Biederman responds, “GOD.”

This is a 23 minute expose well worth watching.

« Return to news items


Share